Advanced Solid Tumors
Conditions
Brief summary
This is a single center, open-label, dose increasing study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and antitumor efficacy of KL340399 intratumoral in patients with advanced solid tumors.
Detailed description
This is a single center, open-label, dose increasing study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and antitumor efficacy of KL340399 intratumoral in patients with advanced solid tumors.The dose increasing method of "BLRM" is used to explore the safety, tolerance and determine the maximum tolerated dose(MTD).
Interventions
DRUGKL340399 Intratumoral
KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
Sponsors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is at least ≥18 years of age (male or female); 2. Patients with histologically and/or cytologically confirmed advanced solid tumors who have failed standard of care, or who have no available standard of care regimen, or who are unqualified for standard of care. Presence of at least one measurable lesion for intratumoral ; 3. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1, estimated survival ≥ 3 months; 4. Adequate organ and bone marrow function (no blood components and cytokines are allowed within 14 days prior to the first dose) ; 5. More than 4 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment, target therapy, and toxicity from previous antitumor therapy returned to baseline or CTCAE≤ grade 1; 6. Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 3 months after the end of dosing; 7. Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.
Exclusion criteria
1. Known history of severe allergies, or allergy to any component of KL340399; 2. Received any previous therapy of STING-activating, or received any immunostimulant therapy within 28 days; 3. Have other malignancies within 5 years; 4. Concomitant or known metastases to brain or central nervous system; 5. Active autoimmune disease; 6. History of major cardiovascular diseases; 7. Uncontrolled systemic diseases; 8. Known of coagulation disorders, hemorrhagic disease; 9. Confirmed serious lung disease or lung disease; 10. Subjects with third space fluid that can not be controled by drainage or other methods; 11. Known active infection; 12. Known HIV, active hepatitis B/C virus; 13. Pregnant or lactating women; 14. Received immunotherapy and had immune related adverse reactions ≥ grade 3; 15. Have received stem cell transplantation or organ transplantation; 16. Receive any live or attenuated live vaccine within 4 weeks; 17. History of serious dementia, altered mental status, or any psychiatric disorder; 18. Evidence of alcohol or drug abuse; 19. Participated in any other clinical trials and received treatment within 4 weeks; 20. Have other factors based on which the investigator considers that the subjects are not appropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects achieving Dose-limiting toxicity (DLT) | From data of initial dose until up to 21 days for treatment | DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug. |
| Maximum Tolerated Dose (MTD) | From data of initial dose until up to 21 days for treatment | The maximum tolerated dose (MTD) is refers to the highest dose at which the patient's DLT incidence exceeding 33% during the first cycle. |
| Incidence of Adverse Events [Safety and Tolerability] | Up to 24 months | Incidence of adverse events of KL340399 as a monotherapy as determined by patient reporting, clinical laboratory test changes from baseline, and clinically significant changes in physical examination data. |
| Recommended Phase 2 Dose (RP2D) | Up to 24 months | The recommended phase 2 dose (RP2D) will be based on a consideration of the totality of data including but not limited to safety data (including DLTs), PK, PD and preliminary efficacy, as available. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 24 months | The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases. |
| Progression Free Survival (PFS) | Up to 24 months | PFS: Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors. |
| Duration of Response (DOR) | Up to 24 months | DOR: Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason. |
| Overall Survival (OS) | Up to 24 months | OS: Time from start of treatment to death due to any reason. |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORJun Guo, Dr.
Peking University Cancer Hospital & Institute
Outcome results
None listed